Skip to content

Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

A Multi-site, Prospective, Observational Study of Autologous Hair Follicle Secretome (aHFS) as an Adjunct to Medical Aesthetic Procedures

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06477172
Enrollment
500
Registered
2024-06-27
Start date
2024-09-09
Completion date
2027-02-01
Last updated
2026-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Procedural Erythema

Brief summary

Non-interventional, multi-site, prospective, open-label, observational, real-world study of autologous hair follicle secretome use.

Detailed description

This non-interventional, observation study is to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product following various medical aesthetic procedures.

Interventions

None listed

Sponsors

Acorn Biolabs Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Male and Female * Ages: 18-60 * Any Fitzpatrick skin type * Planning a medical aesthetic procedure * For subjects receiving hair procedures (closed to enrollment): 1. Androgenic alopecia 2. Traction alopecia 3. Scarring alopecia 4. Stable use of any medication or supplement for hair loss, including finasteride, any other 5 α-reductase inhibitor, minoxidil, steroids, or hormonal products, during the 3 months prior to enrollment in the study is allowed. 5. No intention to start new hair growth medications or change dose of hair growth medications from the time of consent through the end of the study follow-up period. * Undergoing one of the following medical aesthetic procedures: 1. Laser resurfacing of the face (ablative or non-ablative) or Ellacor of the face (Ellacor closed to enrollment) 2. Tixel of the face 3. Keralase of the scalp (scalp treatment closed to enrollment) 4. Acne Scars and Surgery scars, either old or new as long as old scars are also being treated with ablative or non-ablative laser or microneedling (e.g. abdominoplasty, breast reduction/ reconstruction/enhancement, post-weight loss, etc. * Planning to use Acorn Autologous Hair Follicle Secretome cosmetic product

Exclusion criteria

* Pregnant or Breastfeeding * Participation in an interventional clinical trial in the last 30 days * Use of other topical cosmetic products that may confound results * Use of retinoids within 7 days prior to facial procedure * For those receiving hair treatment, must not have had a hair transplant in the treatment area within the past 12 months * Any health condition that in the investigator's opinion should preclude participation in study

Design outcomes

Primary

MeasureTime frameDescription
Post-Procedure Symptoms1-7 daysSymptoms of redness, swelling, oozing, pain, tenderness, crusting, itching and discoloration will be measured using a 1-10 likert scale with 0 being best possible and 10 being worst imaginable.
Downtime Questionnaire1-7 daysQuestionnaire asking what activities would they have done, if it were not for their face appearance. Date of end of downtime captured.

Countries

Canada, United States

Contacts

CONTACTLisa Campbell, PhD
lisa.campbell@acorn.me858-997-7447
STUDY_CHAIRDrew Taylor, PhD

Acorn Biolabs

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 5, 2026